Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis

References

• Lee MP, Lii J, Jin Y, et al. Patterns of systemic treatment for psoriatic arthritis in the US: 2004–2015. Arthritis Care Res. 2018;70(5):791–796.
   Web of Science ®Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065–1073.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–735.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(2):ii14–ii17.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568.
   PubMed Web of Science ®Google Scholar
• Husted JA, Thavaneswaran A, Chandran V, et al. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349–1356.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970.
   PubMed Web of Science ®Google Scholar
• Humira (adalimumab) injection, for subcutaneous use [package insert]. North Chicago, IL: AbbVie Inc.; January 2019.
   Google Scholar
• Cimzia (certolizumab pegol) for injection, for subcutaneous use [package insert]. Smyrna, GA: UCB, Inc.; April 2019.
   Google Scholar
• Enbrel (etanercept) for injection, for subcutaneous use [package insert]. Thousand Oaks, CA: Immunex Corporation; June 2019.
   Google Scholar
• Simponi (golimumab) injection, for subcutaneous use [package insert]. Horsham, PA: Janssen Biotech, Inc.; May 2018.
   Google Scholar
• Remicade (infliximab) lyophilized concentrate for injection, for intravenous use [package insert]. Horsham, PA: Janssen Biotech, Inc.; June 2018.
   Google Scholar
• Cosentyx (secukinumab) injection, for subcutaneous use [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2018.
   Google Scholar
• Stelara (ustekinumab) injection, for subcutaneous or intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc; June 2018.
   Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–881.
   PubMed Web of Science ®Google Scholar
• Otezla (apremilast) tablets, for oral use [package insert]. Summit, NJ: Celgene Corporation; July 2019.
   Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P & T. 2015;40(8):495–500.
   PubMedGoogle Scholar
• Coates LC, FitzGerald O, Helliwell PS, et al. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum. 2016;46(3):291–304.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Myerson GE, Fleischmann R, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724–1734.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benef. 2016;9(9):504–513.
   PubMed Web of Science ®Google Scholar
• Lee EB, Amin M, Wu JJ. Drug survival of apremilast for psoriasis in a real-world setting. J Am Acad Dermatol. 2018;79(4):760–761.
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Care Res. 2019;71(1):2–29.
   Web of Science ®Google Scholar
• Feldman SR, Pelletier CL, Wilson KL, et al. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. J Comp Eff Res. 2019;8(1):45–54.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382–390.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Johnson BH, Fox KM, et al. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24(5):369–373.
   PubMed Web of Science ®Google Scholar
• Chastek B, Fox KM, Watson C, et al. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Therapy. 2012;29(8):691–697.
   PubMed Web of Science ®Google Scholar
• Chastek B, Fox KM, Watson C, et al. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013;24(1):25–33.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. PPA. 2018;12:1483–1503.
   Web of Science ®Google Scholar
• Burgos-Pol R, Martinez-Sesmero JM, Ventura-Cerda JM, et al. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016;107(7):577–590.
   PubMed Web of Science ®Google Scholar